Outlook Therapeutics (OTLK) Return on Equity [ROE] (2020 - 2023)
Outlook Therapeutics' Return on Equity [ROE] was -2301.45% in fiscal Q3 2023 (quarter ended Jun 30, 2023), down 2073.78 percentage points from -227.67% a year earlier and down 1888.23 percentage points from the prior quarter.
Powered by 
Analysis
Outlook Therapeutics (OTLK) Return on Equity [ROE] (2020 - 2023) Analysis & Trends
For FY2022 (ended Sep 30, 2022), Return on Equity [ROE] at Outlook Therapeutics came in at -989.99%, up 440.34 percentage points from FY2021.
- In earlier fiscal years, Return on Equity [ROE] was -1430.33% in FY2021.
- The fiscal Q3 2023 figure marks the lowest quarterly Return on Equity [ROE] in data going back to fiscal Q4 2020.
- Compared with a year earlier, Return on Equity [ROE] has declined for three straight quarters, with an average year-over-year change of -290.12 percentage points over the last seven quarters.
- Per Business Quant data, OTLK's Return on Equity [ROE] in the three fiscal quarters before Q3 2023 was -413.22% (Q2 2023), -549.31% (Q1 2023) and -449.29% (Q4 2022).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 25.32% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | - |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 84.40% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 4.97% |
| 10 | Outlook Therapeutics | 80.68 Mn | 44.93 Mn | -8,265.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -2,301.45% |
| Mar 31, 2023 | -413.22% |
| Dec 31, 2022 | -549.31% |
| Sep 30, 2022 | -449.29% |
| Jun 30, 2022 | -227.67% |
| Mar 31, 2022 | -137.89% |
| Dec 31, 2021 | -194.11% |
| Sep 30, 2021 | -611.38% |
| Jun 30, 2021 | -296.85% |
| Mar 31, 2021 | -793.88% |
| Sep 30, 2020 | -397.60% |
API Access
Outlook Therapeutics Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=OTLK&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "OTLK", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=OTLK&period=max&api_key=YOUR_API_KEY");
const data = await res.json();